Table 1 Baseline clinical characteristics and medications
From: Functional changes of the myocardium in survivors of high-voltage electrical injury
HVEI group (n= 23) | Control group (n= 23) | P-value | |
|---|---|---|---|
Age (years) | 49 ± 11 | 49 ± 11 | 0.95 |
Hypertension | 5 (21.7%) | 6 (26.1%) | 0.73 |
Current smoking | 13 (56.5%) | 8 (34.8%) | 0.14 |
Diabetes | 1(4.3%) | 0 (0%) | 1.00 |
Dyslipidemia | 3 (13.0%) | 3 (13.0%) | 1.00 |
Body mass index (Kg/m2) | 23.9 ± 2.4 | 23.5 ± 2.0 | 0.55 |
Hemoglobin (gm/dl) | 14.7 ± 1.0 | 15.1 ± 1.2 | 0.16 |
Fasting glucose (mg/dl) | 111 ± 18 | 92 ± 10 | <0.01 |
Total cholesterol (mg/dl) | 174 ± 27 | 184 ± 26 | 0.22 |
Creatinine (mg/dl) | 0.8 ± 0.1 | 0.8 ± 0.1 | 0.65 |
High-sensitive C-reactive protein (mg/dl) | 48.5 ± 38.5 | 0.8 ± 0.6 | <0.01 |
Beta-blocker | 1 (4.3%) | 2 (8.7%) | 1.00 |
ACEI/ARB | 2 (8.7%) | 4 (17.4%) | 0.67 |
Calcium channel blocker | 5 (21.7%) | 3 (13.0%) | 0.67 |
Statin | 1 (4.3%) | 2 (8.7%) | 1.00 |